AETHLON MEDICAL INC (AEMD) is a publicly traded Healthcare sector company. As of October 14, 2026, AEMD trades at $5.72 with a market cap of $4.17M and a P/E ratio of -0.61. AEMD moved +0.00% today. Year to date, AEMD is -60.43%; over the trailing twelve months it is -83.47%. Its 52-week range spans $1.41 to $249.60. Analyst consensus is neutral with an average price target of $1.50. Rallies surfaces AEMD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Aethlon Medical CEO Frakes receives 42,000 RSUs under 2020 equity incentive plan: Aethlon Medical granted CEO and CFO James B. Frakes 42,000 restricted stock units on Oct. 8, 2026. The award vests over one year, subject to continued service, and accelerates to full vesting if the proposed merger with North Immunology closes.
| Metric | Value |
|---|---|
| Price | $5.72 |
| Market Cap | $4.17M |
| P/E Ratio | -0.61 |
| EPS | $-10.61 |
| Dividend Yield | 0.00% |
| 52-Week High | $249.60 |
| 52-Week Low | $1.41 |
| Volume | 41.22K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-7.15M |
| Gross Margin | 0.00% |
2 analysts cover AEMD: 0 strong buy, 0 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $1.50.